Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder Syndrome and Detrusor Overactivity

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ion Channel Innovations
ClinicalTrials.gov Identifier:
NCT00495053
First received: June 29, 2007
Last updated: March 21, 2012
Last verified: March 2012

June 29, 2007
March 21, 2012
April 2007
July 2008   (final data collection date for primary outcome measure)
The primary objective of this study is to evaluate all safety parameters occurring subsequent to administration of a single intravesical instillation of study drug. [ Time Frame: 6 months (24 weeks) per participant with an additional 18 month safety follow-up. ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00495053 on ClinicalTrials.gov Archive Site
The secondary objective is to evaluate efficacy of a single intravesical instillation of hMaxi-K compared to the control group. [ Time Frame: 6 months (24 weeks) per participant ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder Syndrome and Detrusor Overactivity
A Phase 1 Multicenter Study of Three Escalating Doses of hMaxi-K Gene Transfer in Female Participants With Overactive Bladder Syndrome and Detrusor Overactivity

The purpose of this study is to evaluate the safety of a new product that uses human gene transfer (called hMaxi-K) when it is given to patients with overactive bladder. Human gene transfer is a new type of therapy that is the process of placing genetic material (DNA or RNA) into a person. The primary objective of this study is to evaluate safety parameters occurring subsequent to administration of a single intravesical instillation of study drug.

Three different dose groups of hMaxi-K will be tested in this study consisting of 5000, 10,000 and 15,000 micrograms. hMaxi-K will be given as a single administration into the bladder through a catheter. Each women's participation in the study will last for up to 24 weeks (followed by an additional 18 month follow-up period).

The safety parameters to be monitored include: adverse events, clinical laboratory tests, electrocardiograms, physical examinations.

The secondary objectives is to evaluate efficacy of a single intravesical instillation of hMaxi-K compared to the control group. Efficacy parameters that will be evaluated are: mean number of micturitions per 24 hours, mean number of urge incontinence episodes per 24 hours, mean number of urgency episodes per 24 hours, overall maximum bladder capacity, number of uninhibited contractions during the cystometry procedure, participant rating of urgency score, participant rating of perceived bladder condition severity, participant assessment of response to treatment, participant rating of Quality of Life (Kings Health Questionnaire), SF-12 Health Survey, International consultation on incontinence questionnaire, weight measurement of accidental bladder leaks.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Overactive Bladder
  • Genetic: hMaxi-K
    Three dose levels (5000µg /90 mL intravesical instillation, 10000µg/90 mL intravesical instillation, and 15000µg/90 mL intravesical instillation)
  • Drug: hMaxi-K
    Gene Transfer
  • Other: Placebo
    placebo (PBS-20% sucrose)
  • Active Comparator: hMaxi-K
    Interventions:
    • Genetic: hMaxi-K
    • Drug: hMaxi-K
  • Placebo Comparator: Placebo
    Interventions:
    • Genetic: hMaxi-K
    • Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21
November 2009
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy women of 18 years of age or older and non-childbearing potential
  • clinical symptoms of overactive bladder for 6 months or longer including at least one of the following:

    1. frequent urination (that is, having to go to the bathroom 8 or more times per day)
    2. symptoms of urinary urgency, which is experiencing a sudden need to pass urine that is difficult to hold back; or the complaint of waking at night two ore more times to urinate
    3. urge urinary incontinence which is that complaint of leakage of urine that cannot be stopped accompanied by or immediately preceded by urgency 5 or more times per week.
  • Non-response or poor tolerance to previous treatment for symptoms of overactive bladder and do not wish to continue with that treatment.

Exclusion Criteria:

  • A woman with a positive serum (HCG) pregnancy test or lactating
  • History of three or more culture documented recurrent urinary tract infections per year
  • Current history or previous diagnosis of painful bladder syndrome (interstitial cystitis) with pain in the region of the pelvis, perineum, or lower abdomen relieved by voiding
  • A life expectancy of less than 12 months
  • Current history of Grade 2 or greater cystocele
  • An indwelling urethral catheter or need for clean intermittent self- catheterization
  • Recent heart attack
  • Uncontrolled diabetes
  • Latex allergy
  • Stress urinary incontinence as determined by observation of the participant coughing while standing with a full bladder and/or response of 2 or 3 on the following Stress Urinary Incontinence question: Do you experience leakage when laughing, coughing, lifting heavy objects or other types of discreet, moderately intense activities? 0=NONE: No leakage 1=MILD: Minimal leakage on rare occasions during these types of activities; easily tolerated; do not use pads for this 2=MODERATE: Enough leakage that it requires occasional use of pads and may interfere with usual activity & tasks 3=SEVERE: Extreme leakage and discomfort that stops all activity &/tasks and requires use of pads on all occasions
Female
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00495053
ION-02
Yes
Ion Channel Innovations
Ion Channel Innovations
Not Provided
Study Director: Arnold Melman, MD Ion Channel Innovations
Ion Channel Innovations
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP